Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Mild Cognitive Impairment
Interventions
DRUG

AL-208

1 dose of 300 mg

DRUG

Placebo

1 dose of placebo

Trial Locations (28)

10016

NYU Medical Center, New York

16502

Consultants in Cardiovascular Diseases Inc., Erie

22042

Inova Fairfax Hospital, Falls Church

23116

Cardiac and Thoracic Surgical Associates, Ltd., Mechanicsville

27610

Carolina Cardiovascular Surgical Associates, PA, Raleigh

27710

Duke University Medical Center, Durham

28405

Memory Assessment and Research Services, Wilmington

30309

Piedmont Hospital Research Institute, Atlanta

30342

The Atlanta Heart and Vascular Research Group, Atlanta

32216

Jacksonville Center for Clinical Research, Jacksonville

33143

Miami Research Associates, South Miami

37212

Vanderbilt University, Nashville

37920

Clinical Research Solutions, PC, Knoxville

43608

St. Vincent Mary Medical Center, Toledo

46804

Indiana/Ohio Heart Cardiothoracic and Vascular Surgeons, Fort Wayne

48532

Cardiothoracic Associates, Flint

60007

Chicago Heart Institute and Vein Clinic, Elk Grove Village

60521

Illinois Heart and Vascular Foundation, Hindsdale

60612

Rush University Medical Center, Chicago

75226

Clinical Cardiovascular Research Center, Dallas

77030

St. Luke's Episcopal Hospital, Houston

92653

Physicians Clinical Research Corp., Laguna Hills

95825

Sacramento Heart and Vascular Research Center, Sacramento

98415

Multicare Health Systems, Tacoma

02115

Brigham & Women's Hospital, Boston

74104-5428

Tulsa Clinical Resesarch, LLC, Tulsa

N6A5A5

London health Sciences Centre, London

M5G2C4

Toronto General Hospital, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allon Therapeutics

INDUSTRY

NCT00404014 - Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery | Biotech Hunter | Biotech Hunter